To examine the potential of combining Bcl-2 family inhibitors with chemotherapy in ovarian cancer, we evaluated a panel of 27 ovarian cancer cell lines for response to the combination of navitoclax (formerly ABT-263) and paclitaxel or gemcitabine. The majority of cell lines exhibited a greater than additive response to either combination, as determined by the Bliss independence model, and more than 50% of the ovarian cell lines exhibited strong synergy for the navitoclax/paclitaxel combination. To identify biomarkers for tumors likely to respond to this combination, we evaluated the protein levels of intrinsic apoptosis pathway components. Bcl-x L appears necessary, but not sufficient, for navitoclax/paclitaxel synergy in vitro, suggesting that exclusion of patients whose tumors have low or undetectable Bcl-x L would enrich for patients responsive to the combination. We evaluated Bcl-x L levels in ovarian cancer tumor tissue from 40 patients (20 taxane responsive and 20 with poor response to taxane), and found that patients with high Bcl-x L were less sensitive to taxane treatment (10/12) Bcl-x L positive patients, p = 0.014). These data support the use of navitoclax in combination with taxane-based therapy in ovarian cancer patients with high levels of Bcl-x L .
Introduction
Ovarian cancer is a major health concern. Although there have been improvements in the treatment of ovarian cancer, it is the sixth most frequent cause of cancer related death in developed countries. A recent report estimated that there were 225,500 new cases of ovarian cancer and 140,00 deaths world-wide due to ovarian cancer in 2008 (1) .
Carboplatin is the mainstay of chemotherapy for ovarian cancer, and addition of either paclitaxel or gemcitabine to carboplatin significantly improves response. Although 75% of ovarian cancer patients respond to frontline therapy of debulking surgery followed by platinum-based therapy, most will experience recurrence (2) . Thus, there is a need for strategies to improve the durability of response to chemotherapy in ovarian cancer. One strategy is to combine chemotherapy with an inhibitor of anti-apoptotic Bcl-2 family proteins to increase cell death after cell cycle arrest (3, 4) .
The family of Bcl-2 related anti-apoptotic proteins includes Bcl-2, Bcl-x L , Bcl-w, A1
(Bfl-1), and Mcl-1. These proteins block cell death by sequestering the pro-apoptotic proteins, Bax and Bak, preventing them from oligomerizing and forming pores in the mitochondrial outer membrane (5) . Elevated expression of Bcl-2, the first anti-apoptotic protein to be causally linked to cancer, allows cells to evade apoptosis (6, 7) . Bcl-2 and
Bcl-x L are frequently expressed at high levels in a variety of cancers, and a survey of gene expression and response to chemotherapy agents in the NCI-60 panel identified
Bcl-x L as a major contributor to chemo-resistance in epithelial cancer cells (8) . Thus, inhibition of Bcl-x L and Bcl-2 might be expected to potentiate the effect of cytotoxic therapy by enhancing the apoptotic response to cellular stress. ABT-737 is a smallmolecule inhibitor of Bcl-2, Bcl-x L , and Bcl-w (9); navitoclax (ABT-263) is an orally bio-available inhibitor with a similar binding profile that is under evaluation in clinical trials (10) (11) (12) . These molecules inhibit Bcl-2 proteins by mimicking the BH3-domain interactions of the pro-apoptotic "BH3-only" protein Bad with the Bcl-2 family proteins, thereby preventing them from sequestering pro-apoptotic executioner proteins Bax and Bak, as well as BH3-only proteins. Navitoclax has been shown to enhance the efficacy of cytotoxic drugs in hematologic and solid-tumor xenograft models (10, (13) (14) (15) . Here we have explored combinations of navitoclax with standard of care agents in greater depth in ovarian cancer cell lines with the aim of estimating the prevalence of a synergistic response in this cancer type and identifying biomarkers predictive of synergy between these agents.
Materials and Methods

Chemicals
Navitoclax (Abbott Laboratories), gemcitabine (Toronto Research Chemicals) and paclitaxel (Sigma-Aldrich) were dissolved in dimethyl sulfoxide (DMSO; SigmaAldrich) and aliquots were stored at -80°C. The experiment was performed twice, and the data are presented as an average of both runs. To evaluate protein levels in response to the inhibitors, cell were arrested in S phase by the addition of thymidine for 24 hours, then washed and released into the indicated compound. Cells were harvested for western blotting starting at 8 hours after release.
Non-adherent and adherent cells were lysed in ice-cold RIPA buffer (Cell Signaling Technology) containing 1 mM Pefabloc, Phosphatase Inhibitor Cocktail 1 and 2 (SigmaAldrich), and complete EDTA-free protease inhibitor tablet (Roche). Equal amounts of protein were subjected to SDS-PAGE (4-12% Bis-Tris; Invitrogen), and protein levels were evaluated by Western blotting.
Image processing and statistics
Relative protein levels were quantified using the ImageJ software (National Institutes of Health), and normalized to β-actin. Statistical analysis was performed using Prism 5 (GraphPad Software). We used ROC curve analysis (ROCR, R package) to evaluate the performance of using Bcl-x L IHC score to predict the response of ovarian cancer patients.
To evaluate the correlation of Bcl-xL and overall survival, we evenly divided the ovarian cancer patients into three groups based on their Bcl-x L IHC scores: high >200, medium >150 and <200, low <150. The analysis of the overall survival was then conducted using Kaplan-Meier curves, which plots the three groups of patients, and Cox proportional hazard, which compares the patients with medium and high IHC scores against the ones with low IHC scores respectively (survival, R package). High Bcl-x L IHC score is associated with poor prognostic (HR=2.8, p value=0.047, without adjusting by any other prognostic marker).
Immunohistochemistry (IHC)
Formalin fixed and paraffin-embedded primary ovarian adenocarcinoma specimens were procured from Cureline (Burlingame, CA) and sectioned at 4 micron onto slides. After deparaffinization and rehydration, sections were processed for Bcl-x L IHC. Antigen retrieval was performed using CC1 standard buffer (Ventana Medical Systems). Sections 
Results
Most Ovarian Cancer Cell Lines Exhibited a Synergistic Response to the
Combination of Navitoclax and Chemotherapy Agents
Navitoclax is the subject of Phase Ib trials in combination with taxanes and with gemcitabine. To determine the potential of navitoclax to enhance the activity of these chemotherapies, we evaluated synergy with gemcitabine or paclitaxel in a panel of 27 ovarian cancer cell lines. We employed a 9 by 7 dose matrix to sample a large range of doses and ratios of agents. Figure 1 shows examples of cell lines that exhibit strong or weak combination effects. In the IGROV-1 cell line, the addition of navitoclax to paclitaxel reduces the IC 50 values and increases the maximum inhibition ( Figure 1A ).
The patterns of inhibition in the dose matrix are more readily apparent when displayed as a heat map ( Figure 1B) . We analyzed combination effects using the Bliss independence model (16) because it allows analysis over the dose matrix and does not require that the individual agents have a measurable IC 50 value, as is often the case with navitoclax. The Bliss score is the difference between the calculated inhibition value if the two agents act independently and the observed combined inhibition values. Positive Bliss scores represent dose combinations where the effect is greater than additive. The heat map of Bliss scores for IGROV-1 ( Figure 1C) shows that there are greater than additive effects across a clinically relevant range of doses for both compounds (11, 17) . In contrast, the TOV21G cell line exhibited minimal synergy across a small dose range. Although there was a small increase in maximal inhibition, there was no significant IC 50 shift ( Figure 1 A-C). To summarize the combination data, we added the Bliss scores of all dose combinations to generate a "Bliss sum" for each cell line. The majority of the ovarian cancer cell lines exhibited positive Bliss sums for the combination of navitoclax and paclitaxel or gemcitabine (Tables 1 and 2 ). This was especially striking in the paclitaxel combinations, where 26 of 27 cell lines had positive Bliss sums. Of these, 14 were classified as having strong synergy (Bliss sum greater than 250). We defined this value empirically, based on data demonstrating good combination effects in xenografts of SK-OV-3 cells (18) . The cell lines that had high Bliss scores tended to have lower levels of paclitaxel inhibition. However, this trend did not attain statistical significance (Table 1) .
A likely explanation for this trend is that cell lines that have weaker responses to singleagent paclitaxel have greater potential to generate high Bliss scores following combination treatment than cell lines that are more sensitive to single-agent paclitaxel (19) . The observation that maximal inhibition is increased by navitoclax suggests strongly that the poor single-agent responses are due, at least in part, to Bcl-2 or Bcl-x L .
In the gemcitabine navitoclax combinations, 25 of 27 cell lines had positive Bliss sums, but only 8 fell into the strong synergy range ( Table 2) . We therefore focused follow up studies on the paclitaxel combinations. As expected, very few cell lines exhibited a strong response to navitoclax alone. Only one cell line, OAW28, had an IC 50 value less than 500 nM. This was confirmed independently in the two studies (Tables 1 and 2 ).
Response to Inhibitor Treatment
To characterize the response to the combination of paclitaxel and navitoclax in more detail, we evaluated response to single agents and the combination with a caspase 3/7 activation assay and western blotting. We selected IGROV-1 and SK-OV-3 as examples of cell lines with very strong and moderately strong synergy. There is modest caspase activation with navitoclax or paclitaxel, with activity strongest after 48 hours.
Addition of navitoclax to paclitaxel enhanced the caspase activation at all paclitaxel doses tested in both cell lines. Interestingly, the peak of activity was shifted to 24 hours To evaluate effects on the intrinsic apoptosis pathway, we partially synchronized cells with a single thymidine block and released them from S phase arrest into navitoclax, paclitaxel, or the combination and harvested cell for western blotting. In the IGROV-1 cells Bcl-x L levels do not change, although we observe a slight mobility shift that is likely due to phosphorylation during mitotic arrest. Bim levels are somewhat higher in navitoclax treated cells. Importantly, we observe that Mcl-1 levels decrease during mitotic arrest (in the presence of paclitaxel). As expected, there is more cell death, indicated by increased levels of cleaved PARP, in the combination. This is likely due to the combination of reduced protective effects of Mcl-1 due to degradation during mitotic arrest and reduced Bcl-x L activity due to the inhibitory effects of navitoclax ( Figure 2C ).
We did not observe an effect on Bcl-x L or bim levels in the SK-OV-3 cell line. However, we did observe the expected decrease in Mcl-1 levels in paclitaxel treated cells. As in the IGROV-1 cells, there was more PARP cleavage in the combination compared to either single agent ( Figure 2D) . Interestingly, the SK-OV-3 cells exhibit some PARP cleavage in response to single agent navitoclax, consistent with the modest single agent activity observed with navitoclax in this cell line (Table 1) . Overall, these data are consistent with a model in which there is enhanced apoptosis in the combination due to a reduction in Mcl-1 during mitotic arrest and inhibition of Bcl-x L by navitoclax.
Levels of Bcl-x L Correlate with Synergy Scores for Navitoclax and Paclitaxel
Because the response to the combination of navitoclax with chemotherapy agents varied among cell lines, we wanted to identify markers that correlated with strong synergy. We measured protein levels of Bcl-2 family members by western blotting and observed a trend with the levels of Bcl-x L and Bliss score ( Figure 3A 
lung cancer (NSCLC) (3), and found a significant correlation with Bliss sum ( Figure 3B ).
Interestingly, Bcl-2 expression was observed in the cell lines with low synergy.
However, this enrichment was not significant using the cutoff of Bliss score greater than 250 for high synergy.
High Levels of Bcl-x L Correlate With Poor Response to Taxane-Based Therapy in
Ovarian Cancer Patients
The cell culture data suggest that a high level of Bcl-x L causes resistance to paclitaxel that can be reduced by Bcl-x L inhibition. To test whether high levels of Bcl-x L contribute to resistance to chemotherapy, we acquired formalin-fixed paraffin-embedded (FFPE) primary-tumor tissue with associated outcome data from 40 ovarian cancer patients that were treated with a taxane-based therapy. Good responders exhibited a minimum of 36 months disease free survival, while poor responders had recurring disease within 12 months. We evaluated Bcl-x L by IHC ( Figure 4A and B) and assigned an H score based on intensity and percentage of stained cells (Supplemental Table 1 ). The poorly responsive patients had a higher median H score than the responsive patients ( Figure 4C ).
We next generated a receiver operator curve (ROC) and determined that the optimal threshold for correlating response with H score was 200 (Supplemental Figure S1 ). If we set a threshold for high Bcl-x L at an H score greater than or equal to 200, 83% of patients with high Bcl-x L had poor response to a paclitaxel based regimen (p = 0.014, Fisher exact test) ( Figure 4D ). These data are consistent with the hypothesis that high Bcl-x L can lead to resistance to taxane-based therapy. Indeed, the patients with high levels of Bcl-x L had a lower overall survival rate (Supplemental Figure S2) . Importantly, the data demonstrate that Bcl-x L level can be evaluated by IHC of patient tissue in a way that correlates with clinical response, thus allowing the possibility of selecting patients for navitoclax combination therapy based on Bcl-x L expression level. In order to estimate the percent of ovarian cancers that might be expected to benefit from this combination, we evaluated an additional 69 ovarian cancer samples with Bcl-x L IHC. We find that 17% have H scores less than or equal to 100, 54% have H scores between 100 and 200, and 29% have H scores greater than or equal to 200. This is consistent with the other sample set in which 30% of the ovarian cancer specimens had H score greater than or equal to 200, and suggests that as many as 30% of ovarian cancer patients could potentially benefit from the combination of navitoclax and a taxane based regimen.
Discussion
In order to test the potential of navitoclax to improve the activity of chemotherapy in ovarian cancer, we evaluated combinations of navitoclax plus paclitaxel ( Figure 5 ) or gemcitabine in a panel of 27 ovarian cancer derived cell lines. We find that both combinations result in growth inhibition levels that are greater than additive in the majority of cell lines tested. Paclitaxel was the superior combination agent, and more than half of the cell lines exhibited Bliss sums greater than 250, a value empirically determined to translate to in vivo models (18) . All of the high synergy cell lines expressed measurable levels of Bcl-x L , while some of the low synergy cell lines did not. Previous work has elucidated a model to explain the differential apoptotic response to mitotic stress that is induced by microtubule poisons such as paclitaxel and docetaxel.
These drugs disrupt the formation of a bipolar spindle with proper attachment of kinetochores. This event produces pro-apoptotic signals, likely due to the activation of Bim (24) (25) (26) , although this is the subject of debate (27) . Cells are protected from apoptosis by the anti-apoptotic proteins, Mcl-1 and Bcl-x L , which are slowly inactivated by ubiquitin-dependent proteolysis (27) (28) (29) or phosphorylation (30), respectively. Thus, regulation of these proteins could act as "clocks" to allow time for repair of the mitotic spindle, but eventually triggers cell death if the spindle assembly checkpoint is not satisfied. This is balanced by an independent clock governing the duration of mitotic arrest, primarily a function of the rate of cyclin B degradation (31, 32). In this model, the variables that govern the balance between mitotic arrest and cell death include baseline levels of the anti-apoptotic proteins (Bcl-x L , Bcl-2 and Mcl-1), and baseline levels of the pro-apoptotic BH-3 only proteins (e.g. Bim). Of these, the baseline level of Bcl-x L appears to be the best correlate to synergy between navitoclax and paclitaxel in ovarian cancer cells.
It has been suggested for some time that Bcl-x L levels contribute to chemo-resistance (8), however, the clinical relevance of this mechanism was unknown. Our data demonstrate that 50% of ovarian tumors classified as poorly responsive to chemotherapy had high levels of Bcl-x L by IHC analysis, suggesting that this mechanism could account for a significant proportion of taxane resistance. Importantly, we see that 83% of the high Bclx L expressing patients were classified as taxane non-responders, suggesting that Bcl-x L levels could be used to identify patients whose response to taxane-based therapy could be or equal to 200, indicating that it may be essential to evaluate Bcl-x L levels in patients to identify those most likely to benefit from the addition of navitoclax to chemotherapy.
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Huang Table 1 Summary of paclitaxel/navitoclax combinations in 27 ovarian cancer cell lines. Navitoclax was dosed in a range of 3 μM to 10 nM in 7 three-fold dilutions, and paclitaxel was dosed in the range of 100 nM to 10 pM in 9 three-fold dilutions. Each value reported is the average of at least 3 independent experiments run in quadruplicate.
IC 50 values and Bliss scores were measured using CellTiterGlo. * % Inhibition at 100 nM paclitaxel and 3 μM navitoclax, SD = standard deviation. Table 2 Summary of gemcitabine navitoclax combinations in 27 ovarian cancer cell lines. Navitoclax was dosed in a range of 3 μM to 10 nM in 7 three-fold dilutions, and gemcitabine was dosed in the range of 3 μM to 0.5 nM in 9 three-fold dilutions. Each value reported is the average of at least 3 independent experiments run in quadruplicate.
IC 50 values and Bliss scores were measured using CellTiterGlo. * % Inhibition at 3 μM gemcitabine and 3 μM navitoclax, SD = standard deviation. 
